{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:09:02Z","timestamp":1789016942434,"version":"build-2803163510"},"reference-count":92,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Clin Med&amp;#65533;Insights&amp;#65533;Arthritis&amp;#65533;Musculoskelet Disord"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>Cannabis-based medicinal products (CBMPs) are an emerging therapeutic option for pain in inflammatory arthritis, yet clinical evidence remains limited. This study aimed to evaluate changes in pain-specific and general health-related outcomes in patients with inflammatory arthritis treated with CBMPs and to characterize the safety profile by examining the incidence and nature of adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Patients treated with CBMPs for inflammatory arthritis\u2013associated pain for \u2a7e24\u2009months were identified from the UK Medical Cannabis Registry. Primary outcomes included changes in patient-reported measures: Brief Pain Inventory (BPI), Pain Visual Analogue Scale (Pain VAS), Short-Form McGill Pain Questionnaire 2 (SF-MPQ-2), EuroQol 5-dimension 5-level (EQ-5D-5L), Generalized Anxiety Disorder-7 (GAD-7), and Single-Item Sleep Quality Scale (SQS) at 1, 3, 6, 12, 18, and 24\u2009months vs baseline. Adverse events were recorded and analysed. Statistical significance was set at\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u2009.050.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 192 patients met inclusion criteria. The CBMP initiation was associated with improvements in BPI Interference, BPI Severity, Pain VAS, SF-MPQ-2, SQS, and EQ-5D-5L index values at all follow-up time points (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u2009.010) and in GAD-7 scores up to 3\u2009months (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u2009.001). Twenty-seven patients (14.06%) reported 296 adverse events: 126 (42.57%) mild, 132 (44.59%) moderate, and 38 (12.84%) severe. No life-threatening events occurred.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The CBMP therapy was associated with reductions in pain and improvements in health-related quality of life among individuals with inflammatory arthritis. Although causality cannot be inferred from this observational design, these findings support the need for randomized controlled trials to determine the efficacy of CBMPs for inflammatory arthritis\u2013related pain.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/11795441261480709","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:20:21Z","timestamp":1789014021000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["UK Medical Cannabis Registry: An Updated Analysis of Inflammatory Arthritis"],"prefix":"10.1177","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1958-0374","authenticated-orcid":false,"given":"Anusha","family":"Sajeev","sequence":"first","affiliation":[{"name":"Medical Cannabis Research Group, Imperial College London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5871-6501","authenticated-orcid":false,"given":"Simon","family":"Erridge","sequence":"additional","affiliation":[{"name":"Medical Cannabis Research Group, Imperial College London, UK"},{"name":"Curaleaf Clinic, London, UK"},{"name":"Department of Surgery and Cancer, Imperial College London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aritra","family":"Datta","sequence":"additional","affiliation":[{"name":"Medical Cannabis Research Group, Imperial College London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evonne","family":"Clarke","sequence":"additional","affiliation":[{"name":"Curaleaf Clinic, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy","family":"McLachlan","sequence":"additional","affiliation":[{"name":"Curaleaf Clinic, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Coomber","sequence":"additional","affiliation":[{"name":"Curaleaf Clinic, London, UK"},{"name":"St George\u2019s University Hospitals NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Rucker","sequence":"additional","affiliation":[{"name":"Curaleaf Clinic, London, UK"},{"name":"Department of Psychological Medicine, King\u2019s College London, UK"},{"name":"South London and Maudsley NHS Foundation Trust, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Platt","sequence":"additional","affiliation":[{"name":"Curaleaf Clinic, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael H.","family":"Sodergren","sequence":"additional","affiliation":[{"name":"Medical Cannabis Research Group, Imperial College London, UK"},{"name":"Curaleaf Clinic, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.5772\/54743"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2022.100519"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(23)00211-4"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkaf031"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-eular.4180"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.24092"},{"issue":"12","key":"e_1_3_2_8_2","first-page":"680","article-title":"The burden of psoriatic arthritis: a literature review from a global health systems perspective","volume":"35","author":"Lee S","year":"2010","unstructured":"Lee S, Mendelsohn A, Sarnes E. The burden of psoriatic arthritis: a literature review from a global health systems perspective. Pharmacy and Therapeutics. 2010;35(12):680-689","journal-title":"Pharmacy and Therapeutics"},{"key":"e_1_3_2_9_2","unstructured":"Wenker KJ Quint JM. Ankylosing spondylitis. In: StatPearls [Internet]: StatPearls Publishing;2025. Accessed August 18 2025. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK470173\/"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0192524"},{"key":"e_1_3_2_11_2","unstructured":"Rheumatoid arthritis costs the economy \u00a34.75bn but care still \u201cdisgracefully low.\u201d Medical News Today. Accessed September 10 2025. https:\/\/www.medicalnewstoday.com\/releases\/290513"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra040226"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10148"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.hco.0000245740.85829.4f"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1080\/08037050410004783"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000029974"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0730-2"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep435"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.171375"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/ejp.1651"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar3353"},{"key":"e_1_3_2_22_2","unstructured":"Queremel Milani DA Davis DD. Pain management medications. In: StatPearls [Internet]. StatPearls Publishing;2025. Accessed August 20 2025. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK560692\/"},{"issue":"11","key":"e_1_3_2_23_2","first-page":"1044","article-title":"[Meta-analysis on the effect and adverse reaction on patients with osteoarthritis and rheumatoid arthritis treated with non-steroidal anti-inflammatory drugs]","volume":"24","author":"Shi W","year":"2003","unstructured":"Shi W, Wang YM, Cheng NN, Chen BY, Li D. [Meta-analysis on the effect and adverse reaction on patients with osteoarthritis and rheumatoid arthritis treated with non-steroidal anti-inflammatory drugs]. Zhonghua Liu Xing Bing Xue Za Zhi. 2003;24(11):1044-1048.","journal-title":"Zhonghua Liu Xing Bing Xue Za Zhi"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0248866"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1988.tb00771.x"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.36076\/ppj.2008\/11\/S105"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2006.04.011"},{"key":"e_1_3_2_28_2","unstructured":"Recommendations. Rheumatoid arthritis in adults: management. NICE Guidance. Published July 11 2018. Accessed August 28 2025. https:\/\/www.nice.org.uk\/guidance\/ng100\/chapter\/Recommendations"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead463"},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","unstructured":"Chou R Hartung D Turner J et al. Opioid Treatments for Chronic Pain. Agency for Healthcare Research and Quality; 2020. Accessed October 20 2025. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK556253\/","DOI":"10.23970\/AHRQEPCCER229"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000868"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120341"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0026-895X(25)09876-1"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.5041\/RMMJ.10129"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/3-540-26573-2_10"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1124\/pr.54.2.161"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1995.2437"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19030833"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000000428"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0707442"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2012.15"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12020307"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107495"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.3389\/fncir.2021.816747"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28165980"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000001929"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1034"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0267420"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0320756"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1177\/20503245231167373"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1177\/20503245231164718"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0272241"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1186\/s42238-022-00154-9"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000556"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1002\/npr2.12183"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"e_1_3_2_57_2","unstructured":"The supply manufacture importation and distribution of unlicensed cannabis-based products for medicinal use in humans \u2018specials\u2019. Accessed September 10 2025. https:\/\/assets.publishing.service.gov.uk\/media\/5e58eefb86650c53a363f77c\/Cannabis_Guidance__unlicensed_CBPMs__updated_2020.pdf"},{"key":"e_1_3_2_58_2","unstructured":"Decentralised manufacture: UK Guideline on Good Manufacturing Practice (GMP). GOV.UK. Accessed September 10 2025. https:\/\/www.gov.uk\/guidance\/decentralised-manufacture-uk-guideline-on-good-manufacturing-practice-gmp"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.3414\/ME17-01-0051"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jphys.2016.05.008"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1089\/can.2016.0025"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1080\/15360288.2023.2174633"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0000000000000933"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-8-148"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2007.09.005"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.3171\/2020.11.SPINE201431"},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00541514"},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jse.2009.03.021"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.10.1092"},{"key":"e_1_3_2_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2020.01.032"},{"key":"e_1_3_2_71_2","doi-asserted-by":"publisher","DOI":"10.5664\/jcsm.7478"},{"key":"e_1_3_2_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.02.008"},{"key":"e_1_3_2_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2009.01.258"},{"key":"e_1_3_2_74_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-017-3595-8"},{"key":"e_1_3_2_75_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjebm-2025-114101"},{"key":"e_1_3_2_76_2","doi-asserted-by":"publisher","DOI":"10.1093\/pm\/pnab050"},{"key":"e_1_3_2_77_2","doi-asserted-by":"publisher","DOI":"10.1080\/17581869.2025.2467025"},{"key":"e_1_3_2_78_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-010818-021542"},{"key":"e_1_3_2_79_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.43848"},{"key":"e_1_3_2_80_2","doi-asserted-by":"publisher","DOI":"10.1159\/000489291"},{"key":"e_1_3_2_81_2","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2022.2017771"},{"key":"e_1_3_2_82_2","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2023.2181696"},{"key":"e_1_3_2_83_2","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2023.2183841"},{"key":"e_1_3_2_84_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-023-06399-3"},{"key":"e_1_3_2_85_2","doi-asserted-by":"publisher","DOI":"10.1111\/papr.13438"},{"key":"e_1_3_2_86_2","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsab149"},{"key":"e_1_3_2_87_2","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.70124"},{"key":"e_1_3_2_88_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.626853"},{"key":"e_1_3_2_89_2","doi-asserted-by":"publisher","DOI":"10.1080\/15360288.2024.2340076"},{"key":"e_1_3_2_90_2","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2022.2155139"},{"key":"e_1_3_2_91_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.071178"},{"key":"e_1_3_2_92_2","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2023.2195551"},{"key":"e_1_3_2_93_2","unstructured":"Drug misuse in England and Wales \u2013 Office for National Statistics. Accessed October 27 2025. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/crimeandjustice\/articles\/drugmisuseinenglandandwales\/yearendingmarch2024"}],"container-title":["Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11795441261480709","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/11795441261480709","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11795441261480709","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:20:23Z","timestamp":1789014023000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/11795441261480709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":92,"alternative-id":["10.1177\/11795441261480709"],"URL":"https:\/\/doi.org\/10.1177\/11795441261480709","relation":{},"ISSN":["1179-5441","1179-5441"],"issn-type":[{"value":"1179-5441","type":"print"},{"value":"1179-5441","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"article-number":"11795441261480709"}}